Havana, May 13 (RHC) -- More than 100 Cuban and foreign researchers continue debating Wednesday in Havana the development and production of CIMAvax-EGF -- the first therapeutic vaccine for lung cancer to be registered in the world.

The two-day event opened on Tuesday at Havana's Conference Center, aiming to provide a platform for the promotion of this breakthrough drug and discuss strategies for its implementation.

The forum has included key lectures by prominent figures in the sector, including Agustin Lage, director of the Center of Molecular Immunology.

In statements to Prensa Latina, Lage explained that the lung cancer vaccine Cimavax-EGF is opening its way worldwide. Several clinical trials are being conducted in a number of European and Latin American countries and interest in this product is growing, particularly in the United States.